The biotech market faced continued pressure last week amid broader macroeconomic and political uncertainty, with investor sentiment remaining weak and capital markets activity slowing. Data, in part from DealForma, highlights ongoing M&A dynamics and a significant surge in licensing deals from Chinese biotechs. Read the article here
